90390-11-7

Usage

Uses

Used in Organic Synthesis:
N-METHYL-N-[4-(TRIFLUOROMETHYL)BENZYL]AMINE is used as a reagent and building block for the preparation of various pharmaceuticals, agrochemicals, and other fine chemicals. Its nucleophilic nature allows it to participate in a range of reactions, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-METHYL-N-[4-(TRIFLUOROMETHYL)BENZYL]AMINE is utilized as a key intermediate in the development of new drugs. Its unique structure and reactivity contribute to the creation of novel therapeutic agents with potential applications in treating various diseases.
Used in Agrochemical Industry:
N-METHYL-N-[4-(TRIFLUOROMETHYL)BENZYL]AMINE is also employed in the agrochemical sector, where it serves as a precursor for the synthesis of new pesticides and other agricultural chemicals, aiming to enhance crop protection and yield.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, N-METHYL-N-[4-(TRIFLUOROMETHYL)BENZYL]AMINE has been studied for its potential applications, including its role as a catalyst in specific chemical reactions that could lead to the discovery of new pharmaceutical compounds with improved efficacy and selectivity.

InChI:InChI=1/C9H10F3N/c1-13-6-7-2-4-8(5-3-7)9(10,11)12/h2-5,13H,6H2,1H3/p+1

Upstream product

• 67-56-1 methanol 
• 3300-51-4 p-Trifluoromethylbenzylamine 
• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 121372-62-1 N-{[3-(trifluoromethyl)phenyl]methylidene}methanamine 
• 911101-44-5 N-(4-trifluoromethylbenzylidene)methanamine 

Downstream Products

• 93683-73-9 6-[Methyl-(4-trifluoromethyl-benzyl)-amino]-3-nitro-pyridine-2-carbonitrile 
• 1026979-50-9 N-Methyl-2-(4-nitro-phenoxy)-N-(4-trifluoromethyl-benzyl)-acetamide 
• 433309-01-4 2-{4-methoxy-3-[methyl-(4-trifluoromethyl-benzyl)-carbamoyl]-benzyl}-butyric acid ethyl ester 
• 93683-86-4 3-Amino-6-[methyl-(4-trifluoromethyl-benzyl)-amino]-pyridine-2-carbonitrile 
• 93683-98-8 N⁶-Methyl-N⁶-(4-trifluoromethyl-benzyl)-pyrido[3,2-d]pyrimidine-2,4,6-triamine 
• 145942-63-8 N-methyl-N-(4-trifluoromethylbenzyl)-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)-2-butane]sulfonamide 
• 145942-83-2 N-methyl-N-(4-trifluoromethylbenzyl)-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1-imidazolyl)-2-butane]sulfonamide 
• 1123813-12-6 (R)-N₂-[4-(trifluoromethyl)benzyl]-N₁-(4-chlorophenyl)-N₂-methylpyrrolidine-1,2-dicarboxamide 
• 1459695-19-2 C₂₅H₁₉ClF₅N₃O₂S 
• 1459695-20-5 C₂₄H₁₈ClF₅N₄O₂S 
• 1459695-42-1 C₃₂H₃₂F₅N₃O₂S 
• 1479567-47-9 tert-butyl methyl(4-(trifluoromethyl)benzyl)carbamate 

Relevant academic research and scientific papers

Selective Monomethylation of Amines with Methanol as the C1 Source

The N-monomethyl functionality is a common motif in a variety of synthetic and natural compounds. However, facile access to such compounds remains a fundamental challenge in organic synthesis owing to selectivity issues caused by overmethylation. To address this issue, we have developed a method for the selective, catalytic monomethylation of various structurally and functionally diverse amines, including typically problematic primary aliphatic amines, using methanol as the methylating agent, which is a sustainable chemical feedstock. Kinetic control of the aliphatic amine monomethylation was achieved by using a readily available ruthenium catalyst at an adequate temperature under hydrogen pressure. Various substrates including bio-related molecules and pharmaceuticals were selectively monomethylated, demonstrating the general utility of the developed method.

Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists

Monocyte infiltration is implicated in a variety of diseases including multiple myeloma, rheumatoid arthritis, and multiple sclerosis. C-C chemokine receptor 1 (CCR1) is a chemokine receptor that upon stimulation, particularly by macrophage inflammatory protein 1a (MIP-1a) and regulated on normal T-cell expressed and secreted (RANTES), mediates monocyte trafficking to sites of inflammation. High throughput screening of our combinatorial collection identified a novel, moderately potent CCR1 antagonist 3. The library hit 3 was optimized to the advanced lead compound 4. Compound 4 inhibited CCR1 mediated chemotaxis of monocytes with an IC50 of 20 nM. In addition, the compound was highly selective over other chemokine receptors. It had good microsomal stability when incubated with rat and human liver microsomes and showed no significant cytochrome P450 (CYP) inhibition. Pharmacokinetic evaluation of the compound in the rat showed good oral bioavailability.

TACHYKININ RECEPTOR ANTAGONISTS

The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

Imidazole compounds

A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

Isomerization of meso diamines into their C2 symmetrical d,l isomers

An efficient isomerization method is disclosed which allows the obtention of the useful d,l isomers of C2 symmetrical diamines, starting from their meso isomer.

Benzylamines: Synthesis and evaluation of antimycobacterial properties

The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (MIC 10.2 μg/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 μg/mL), and N-butyl-3,5-difluorobenzylamine (MIC 6.4 μg/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combination of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.